Aditxt (NASDAQ:ADTX) stock is rising higher on Wednesday after the company notified investors of an update on a clinical trial conducted by its subsidiary Pearsanta.
According to a press release from Aditxt, Pearsanta has submitted a Clinical Trial Translational Endpoints Research Award proposal to the Congressionally Directed Medical Research Programs (CDMRP) of the Department of Defense.
Aditxt notes that this proposal seeks to validate a novel assay based on Pearsanta’s Mitomic Technology. The goal would be to use this for the “early detection of ovarian cancer.”
Chris Mitton, President of Pearsanta, said the following about this update:
“Submitting this proposal to the CDMRP is another step in our mission to revolutionize early cancer detection. Our proprietary Mitomic Technology aims to provide a reliable, non-invasive, and effective blood test that can lead to earlier detection, more effective treatments, and, ultimately, save lives.”
ADTX Stock Movement Today
With this news comes heavy trading of ADTX stock today. That has more than 97 million shares changing hands as of this writing. This is a massive increase compared to its daily average of about 615,000 shares.
ADTX stock is up 48.8% as of Wednesday afternoon.
There are more stock market stories ready to go below!
We have all of the hottest stock market news available on Wednesday! That includes what’s going on with shares of Novo Nordisk (NYSE:NVO) stock, Sunrun (NASDAQ:RUN) stock and political trades today. All of that news is ready to go at the links below!
More Wednesday Stock Market News
- NVO Stock Alert: Why Is Novo Nordisk Down 8% Today?
- RUN Stock Alert: Surprise! Why Sunrun Stock Is Up 17% Today.
- The Top Stocks Politicians Are Buying and Selling This Week
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
